Barinthus Biotherapeutics

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity and cancer. 

Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b
Biotech

Barinthus enters reverse merger with metabolic disease biotech

The merged entity will work to advance Clywedog’s diabetes portfolio plus Barinthus’ immunology and immunology program.
Gabrielle Masson Sep 30, 2025 10:39am
parachute sunset paragliding chutes

Stanford economist is Trump's NIH pick—Chutes & Ladders

Dec 6, 2024 8:30am
layoffs cut staff reduction workforce

Barinthus lays off 25%, sidelines prostate cancer program

Jun 13, 2024 5:30am
hawaii parasail ocean

BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

May 3, 2024 8:30am
arrow miss target fail attempt try

Barinthus HPV drug doesn't prove efficacy

Apr 19, 2024 9:50am
shot in the arm vaccine strong covid booster

Barinthus' gets $35M booster from CEPI to develop MERS shot

Dec 21, 2023 10:10am